Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionJohn J.V. McMurray, Anna-Maria Langkilde, Akshay S. Desai et al.|New England Journal of Medicine|2019Cited by 6.8k
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection FractionScott D. Solomon, Subodh Verma, John J.V. McMurray et al.|New England Journal of Medicine|2024Cited by 693
Baseline Characteristics of Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF TrialScott D. Solomon, Dirk von Lewinski, John W. Ostrominski et al.|European Journal of Heart Failure|2024Cited by 62
Cardio-Renal-Metabolic Overlap, Outcomes, and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection FractionJohn W. Ostrominski, Muthiah Vaduganathan, Jorge Thierer et al.|JACC Heart Failure|2023Cited by 39
Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trialJohn W. Ostrominski, Scott D. Solomon, Muthiah Vaduganathan et al.|European Journal of Heart Failure|2022Cited by 32